Skip to content

Scott Gottlieb insights from Forbes posts

March 11, 2017

Donald Trump has nominated Scott Gottlieb, a physician and policy expert at the American Enterprise Institute, as the next commissioner at the Food and Drug Administration. Gottlieb edged out Jim O’Neill, a libertarian venture capitalist backed by billionaire investor Peter Thiel, for the nod.

As Gottlieb prepares for the his Senate confirmation hearings, there’s likely to be lots of interest in his public thoughts on healthcare. Here at Forbes, we’ve been lucky to count Scott among our contributors for many years. His writings here reveal the sharp mind of a man who doesn’t believe the system is fundamentally broken, but who is distrustful of bureaucracy as a solution and attuned to the way that small policy changes can have outside effects. Here are a few standouts. For some, I’ve added comments; for the others, I’ve excerpted Gottlieb’s own words.

EpiPen Shows A Path To Solve The Bigger Drug Pricing Challenge

This is one for those wondering what Gottlieb might do as FDA commissioner: he will almost certainly try to streamline the FDA’s approach with regard to “complex generics” like EpiPen, which involve, for instance, both a drug and a device. Here, he goes into detail as to how that process could be fixed.

How Congress Could Make Drug Pricing More Rational

Another problem EpiPen laid bare: the fact that most of the competition around drug prices takes place in the form of rebates that are paid to pharmacy benefit managers and employers, not consumers. In one of my personal favorites of his pieces, Gottlieb argues that this policy has roots in the way companies responded to HillaryCare decades ago.

FDA Needs To Change How It Regulates Novel Technologies

“FDA needs to more closely focus is organizational structure and its regulatory programs on measures of risk, and move away from its structural legacy that oriented its review programs mostly around discrete clinical areas of medicine.”

Theranos Woes Offer Lesson In How Labs Should Be Regulated

Of the many intrigues surrounding Elizabeth Holmes and her battered lab company Theranos, one of the more curious is her established support for increased regulation of her industry.”

Medicare Has Stopped Paying Bills For Medical Diagnostic Tests. Patients Will Feel The Effects

This is the paradigmatic Gottlieb post: a small, seemingly mind-numbing change in the rules around diagnostic tests was affecting patients. So he told us about it.

Obamacare Faces A ‘Death Spiral’ — But It Turns On The Declining Participation Of Health Plans, Not Just Rising Premiums

Like most conservative health writers in 2013, Gottlieb was very concerned about the negative effects of the Affordable Care Act. This was one of the best of those posts: a clear explanation of how the dreaded “death spiral” might happen. As FDA Commissioner, Gottlieb would have almost nothing to do with the ObamaCare replacement.

The Zika Funding Fight Isn’t Over Planned Parenthood

“A spat over money for Planned Parenthood isn’t what’s holding up federal funding to fight the Zika virus. Nor are Republicans, for that matter, the ones now standing in the way,” Gottlieb wrote. “Democrats are filibustering the funding bill largely because Republicans have insisted that the legislation be “paid for” with cuts in other areas of spending. Knowing it would be hard to justify blocking Zika funding over budget arcana, some critics have cast most of their protests under the guise of a fight over abortion.”

 What Trump Should Have Said On Drug Prices

“The debate over drug pricing isn’t new. Nor is the call for importation as a way to try and circumvent some of these costs. But the evolution in these two issues reveals why the Trump plan–while perhaps good politics–will offer consumers little relief.”

How The Feds Discourage Prescription Drug Competition

“Drug companies can rarely make claims around the value of their medicines.”

http://bit.ly/2nrDS1P

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: